| Status: Under consideration by AWMSG Scrutiny Panel | |
Treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. Scrutiny panel considered bimekizumab was suitable for a full assessment. |
|
Medicine details |
|
| Medicine name | bimekizumab (Bimzelx®) |
| Formulation | subcutaneous injection |
| Reference number | 4510 |
| Indication | As above |
| Company | UCB Pharma Ltd |
| BNF chapter | Skin |
| Assessment type | Under consideration |
| Status | Under consideration by AWMSG Scrutiny Panel |
| Scrutiny Panel meeting date | 07/08/2025 |
| NICE guidance | TA1028: Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal) |
| Further information Bimekizumab (Bimzelx®) is suitable for a full HTA assessment via the Licensed Medicines One Wales Medicines Assessment Group (LOWMAG). Unmet clinical need has been identified. There are no UK clinical guidelines currently recommending this treatment and this medicine has not been appraised by NICE (NICE terminated). |
|